Novo Dr Ltd.

Novo Dr Ltd. company information, Employees & Contact Information

Explore related pages

Related company profiles:

NOVO DR Ltd. develops & manufactures cutting edge portable, flat-panel, digital X-ray inspection systems for the Security, NDT and science and art sectors. ____________________________________________________________________________ ____________________________________________________________________________ Combining our decades of experience and intensive R&D working with the world’s most prominent companies and organizations we are now able to take portable digital radiography to the next level and produce game changing product using groundbreaking technology. Every inch of every product gets our undivided full attention. We carefully examine every part of every component in our systems – from design and material, through technology, safety and usability - to ensure it’s engineered for outstanding performance and durability. Today we provide the best of its kind portable digital radiography systems in the market emphasizing the following strong points: Highest image quality – using the most advanced sensors and proprietary algorithm Portability – complete set is lighter and easier to carry than any product offered elsewhere and provides over 16 hours of continuous operation using internal batteries. Efficient user experience – our systems allow easy control and image analysis using a native touch software on one or multiple tablets simultaneously to improve safety and productivity. Field work optimization – systems are exceptionally durable, designed for the harshest of conditions and are completely weather proof. Contact us for more information or if you wish to become a reseller!

Company Details

Employees
31
Founded
-
Industry
Defense And Space Manufacturing
NAICS
Guided Missile and Space Vehicle Manufacturing
Looking for a particular Novo Dr Ltd. employee's phone or email?

Novo Dr Ltd. Questions

News

Cost will be key for Novo Nordisk's Wegovy pill, says Dr. Patel - CNBC

Cost will be key for Novo Nordisk's Wegovy pill, says Dr. Patel CNBC

Novo Nordisk CEO warns of layoffs as Wegovy challenge heats up - Reuters

Novo Nordisk CEO warns of layoffs as Wegovy challenge heats up Reuters

Inhibiting heme piracy by pathogenic Escherichia coli using de novo-designed proteins - Nature

Inhibiting heme piracy by pathogenic Escherichia coli using de novo-designed proteins Nature

Novo Nordisk to sue KBP Biosciences over alleged fraudulent claims on kidney disease drug - Fierce Biotech

Novo Nordisk to sue KBP Biosciences over alleged fraudulent claims on kidney disease drug Fierce Biotech

Drug Company to Share Revenues With Indigenous People Who Donated Their Genes - The New York Times

Drug Company to Share Revenues With Indigenous People Who Donated Their Genes The New York Times

Dr. Reddy’s secures early win in Novo Nordisk’s ‘Ozempic’ infringement claim - Managing Intellectual Property

Dr. Reddy’s secures early win in Novo Nordisk’s ‘Ozempic’ infringement claim Managing Intellectual Property

Dr Reddy's plans to launch generic of Novo's weight-loss drug next year, CEO says - The Economic Times

Dr Reddy's plans to launch generic of Novo's weight-loss drug next year, CEO says The Economic Times

Novo Nordisk should be thinking about 'what's next,' says Dr. Kavita Patel - CNBC

Novo Nordisk should be thinking about 'what's next,' says Dr. Kavita Patel CNBC

India's Dr Reddy's plans to launch generic obesity drugs in 87 countries next year, CEO says - Reuters

India's Dr Reddy's plans to launch generic obesity drugs in 87 countries next year, CEO says Reuters

Novo Nordisk elevates Dr Gaurav Yadav as Cardiometabolic Medical Director for Business Area Africa... - Medical Dialogues

Novo Nordisk elevates Dr Gaurav Yadav as Cardiometabolic Medical Director for Business Area Africa... Medical Dialogues

Potential conflicts of interest may haunt Dr. Oz’s confirmation to run Medicare, Medicaid - The Washington Post

Potential conflicts of interest may haunt Dr. Oz’s confirmation to run Medicare, Medicaid The Washington Post

Hyderabad-based Dr Reddy’s not to sell Novo Nordisk’s Ozempic-like drug in India - Telangana Today

Hyderabad-based Dr Reddy’s not to sell Novo Nordisk’s Ozempic-like drug in India Telangana Today

Delhi HC Bars Dr. Reddy’s from Selling Ozempic-Like Medicine Amid Novo Nordisk Patent Row - outlookbusiness.com

Delhi HC Bars Dr. Reddy’s from Selling Ozempic-Like Medicine Amid Novo Nordisk Patent Row outlookbusiness.com

Dr. Reddy’s tells Delhi High Court it will manufacture and export, but not sell, Ozempic-like drug in India in Novo Nordisk's Suit - Bar and Bench

Dr. Reddy’s tells Delhi High Court it will manufacture and export, but not sell, Ozempic-like drug in India in Novo Nordisk's Suit Bar and Bench

A surgical robotics co-founder offers lessons from the de novo pathway - Medical Design & Outsourcing

A surgical robotics co-founder offers lessons from the de novo pathway Medical Design & Outsourcing

Delhi HC restrains Dr Reddy’s, OneSource in Novo Nordisk weight loss drug patent case - CNBC TV18

Delhi HC restrains Dr Reddy’s, OneSource in Novo Nordisk weight loss drug patent case CNBC TV18

A generative deep learning approach to de novo antibiotic design - ScienceDirect.com

A generative deep learning approach to de novo antibiotic design ScienceDirect.com

Delhi HC seeks Dr Reddy's reply in Novo patent dispute - The Economic Times

Delhi HC seeks Dr Reddy's reply in Novo patent dispute The Economic Times

Novo Nordisk to lay off 9,000 workers as new CEO aims to save $1.3B per year by late 2026 - Fierce Pharma

Novo Nordisk to lay off 9,000 workers as new CEO aims to save $1.3B per year by late 2026 Fierce Pharma

Novo preparing for early launch of weight-loss drug Wegovy in India - Reuters

Novo preparing for early launch of weight-loss drug Wegovy in India Reuters

We Know Where New Weight Loss Drugs Came From, but Not Why They Work (Published 2023) - The New York Times

We Know Where New Weight Loss Drugs Came From, but Not Why They Work (Published 2023) The New York Times

HLA-DR/DQ eplet mismatch predicts de novo donor-specific antibody development in multi-ethnic Southeast Asian kidney transplant recipients on different immunosuppression regimens - Frontiers

HLA-DR/DQ eplet mismatch predicts de novo donor-specific antibody development in multi-ethnic Southeast Asian kidney transplant recipients on different immunosuppression regimens Frontiers

Invetx Appoints Dr. Marcus Remmers, Novo Holdings Partner and Animal Health Industry Leader, to Board of Directors - Business Wire

Invetx Appoints Dr. Marcus Remmers, Novo Holdings Partner and Animal Health Industry Leader, to Board of Directors Business Wire

Compounded semaglutide associated with at least 10 deaths, Novo Nordisk CEO warns - CNN

Compounded semaglutide associated with at least 10 deaths, Novo Nordisk CEO warns CNN

Meet Dr. Anup Sabharwal | Novo Nordisk U.S. Perspectives Blog - Novo Nordisk U.S. Website

Meet Dr. Anup Sabharwal | Novo Nordisk U.S. Perspectives Blog Novo Nordisk U.S. Website

De novo design of modular peptide-binding proteins by superhelical matching - Nature

De novo design of modular peptide-binding proteins by superhelical matching Nature

Andrew R. Novo - Center for European Policy Analysis (CEPA)

Andrew R. Novo Center for European Policy Analysis (CEPA)

Wegovy use among US teens up 50% as obesity crisis worsens - Reuters

Wegovy use among US teens up 50% as obesity crisis worsens Reuters

Dr. Reddy’s to expand GLP-1 portfolio with focus on obesity and diabetes drug markets - Mint

Dr. Reddy’s to expand GLP-1 portfolio with focus on obesity and diabetes drug markets Mint

Wegovy maker Novo Nordisk sponsored British pharmacies in pursuit of sales - The Guardian

Wegovy maker Novo Nordisk sponsored British pharmacies in pursuit of sales The Guardian

Bridging the Gap Between Stem Cell Therapy Research and Clinical Trials - Technology Networks

Bridging the Gap Between Stem Cell Therapy Research and Clinical Trials Technology Networks

Exclusive: Most patients stop using Wegovy, Ozempic for weight loss within two years - Reuters

Exclusive: Most patients stop using Wegovy, Ozempic for weight loss within two years Reuters

What Is Ozempic and Why Is It Getting So Much Attention? (Published 2022) - The New York Times

What Is Ozempic and Why Is It Getting So Much Attention? (Published 2022) The New York Times

Is Ozempic Safe For Weight Loss? Doctors Share Benefits And Risks - TODAY.com

Is Ozempic Safe For Weight Loss? Doctors Share Benefits And Risks TODAY.com

How a love story launched the company behind Ozempic, Wegovy | 60 Minutes - CBS News

How a love story launched the company behind Ozempic, Wegovy | 60 Minutes CBS News

Ozempic and Wegovy Don’t Cost What You Think They Do (Published 2023) - The New York Times

Ozempic and Wegovy Don’t Cost What You Think They Do (Published 2023) The New York Times

Patients Are Suing Over Alleged Side Effects of Weight-Loss Drugs - Time Magazine

Patients Are Suing Over Alleged Side Effects of Weight-Loss Drugs Time Magazine

Biocon eyes generic Wegovy obesity drug launch in India, Canada in next 2 years, CEO says - Reuters

Biocon eyes generic Wegovy obesity drug launch in India, Canada in next 2 years, CEO says Reuters

You’ve Lost Weight Taking New Obesity Drugs. What Happens if You Stop? (Published 2024) - The New York Times

You’ve Lost Weight Taking New Obesity Drugs. What Happens if You Stop? (Published 2024) The New York Times

India pharma companies develop versions of Wegovy to get in on weight-loss windfall - Reuters

India pharma companies develop versions of Wegovy to get in on weight-loss windfall Reuters

What the Scientists Who Pioneered Weight-Loss Drugs Want You to Know - WIRED

What the Scientists Who Pioneered Weight-Loss Drugs Want You to Know WIRED

Wegovy shown to reduce risk of heart attack, stroke in major cardiovascular trial - CNN

Wegovy shown to reduce risk of heart attack, stroke in major cardiovascular trial CNN

Director SKIMS Dr Mohd Ashraf Ganie along with MD of Novo Nordisk, Vikrant Shrotriya and others during signing of an MoU. - Daily Excelsior

Director SKIMS Dr Mohd Ashraf Ganie along with MD of Novo Nordisk, Vikrant Shrotriya and others during signing of an MoU. Daily Excelsior

Revealed: experts who praised new ‘skinny jab’ received payments from drug maker - The Guardian

Revealed: experts who praised new ‘skinny jab’ received payments from drug maker The Guardian

Working Life: Dr Todd Hobbs, Vice President and Chief Medical Officer, Novo Nordisk - Pharmafile

Working Life: Dr Todd Hobbs, Vice President and Chief Medical Officer, Novo Nordisk Pharmafile

‘A Game Changer’: Drug Brings Weight Loss in Patients With Obesity (Published 2021) - The New York Times

‘A Game Changer’: Drug Brings Weight Loss in Patients With Obesity (Published 2021) The New York Times

Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma - Nature

Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma Nature

Health pro: Dr. Novo helps you look, feel your best - Florida Today

Health pro: Dr. Novo helps you look, feel your best Florida Today

Revealed: maker of Wegovy ‘skinny jab’ is funding NHS weight-loss services - The Guardian

Revealed: maker of Wegovy ‘skinny jab’ is funding NHS weight-loss services The Guardian

Researcher receives prize for huge contribution to modern treatment of diabetes and obesity - Novo Nordisk Fonden

Researcher receives prize for huge contribution to modern treatment of diabetes and obesity Novo Nordisk Fonden

Novo Nordisk found in breach of transparency standards by PMCPA - University of Bath

Novo Nordisk found in breach of transparency standards by PMCPA University of Bath

Dr. Hailey Banack Appointed Inaugural Novo Nordisk Research Professor in Health Equity of Chronic Illness Prevention - Dalla Lana School of Public Health

Dr. Hailey Banack Appointed Inaugural Novo Nordisk Research Professor in Health Equity of Chronic Illness Prevention Dalla Lana School of Public Health

Novo Nordisk (NVO) - StreetInsider

Novo Nordisk (NVO) StreetInsider

New Year's Eve (2011) ⭐ 5.6 | Comedy, Romance - IMDb

New Year's Eve (2011) ⭐ 5.6 | Comedy, Romance IMDb

Interview with Dr. Alan Moses, Global CMO, Novo Nordisk - Diabetes In Control

Interview with Dr. Alan Moses, Global CMO, Novo Nordisk Diabetes In Control

Faculty member receives grant from Novo Nordisk to study potential cause of obesity - UBC Faculty of Medicine

Faculty member receives grant from Novo Nordisk to study potential cause of obesity UBC Faculty of Medicine

Top Novo Dr Ltd. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant